Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance study of TS-142 in healthy adult subjects
jRCT2031210027Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vornorexant in Insomnia, sponsored by Taisho Pharmaceutical. Primary endpoints: Radioactivity concentration in whole blood and plasma, Cumulative urinary and fecal recovery of total radioactivity and mass balance and 4 more. Started Apr 2021; status: completed.
02
Drugs
vornorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on jRCT2031210027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210027.